O3-AHT has improved my life and reduced symptoms from neuropathic pain, neurological and autoimmune disorders. It is a core treatment, administered twice a month as an IV infusion treatment.
Phase one of the clinical trial (on self) was initiated in January 2023 and will conclude December 2023. The results will be published in 2024. The initial results are promising but more time is needed to prove my hypothesis. I am publishing various aspects of early treatments to educate people on improvement in my health that may be applicable to others' health. My research from 2020 thru 2022 will be presented at a later date.
My initial research trials of O3-AHT have resulted in greater “cellular homeostasis” in the restoration of the nervous system and minimize effects of autoimmune disorders.
What were the end results?
Increased energy levels
Weight loss (combined with diet) with increased lean muscle mass
Increased physical activity
Increased cardiovascular endurance
Calmed nervous system
Pain score reduction
Increased muscle mass and strength
Increased muscle endurance.
My research on O3-AHT proved that this is a viable core treatment for me. O3-AHT is most effective when combined with a gluten-free, dairy-free and sugar-free diet. The best approach is first changing your diet as inflammation feeds off of inflammatory foods. By eliminating and replacing those foods with non-processed, natural alternatives, inflammation is reduced.
Comments